Jiangsu Hengrui Medicine (600276.SS) Earnings Analysis

Jiangsu Hengrui Medicine (600276.SS) next reports earnings on 2026-08-20, consensus EPS 0.3717 CNY. Last quarter (2026-04-22) it beat with EPS 0.3369 CNY vs 0.3275 CNY est (+2.9%). It has beaten estimates in 4/8 recent quarters (50%). Trailing P/E 43.93.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 600276.SS next report earnings?

Next earnings date2026-08-20
Consensus EPS estimate0.3717 CNY
Revenue estimate9.02B

600276.SS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-220.3369 CNY0.3275 CNY+2.9%Beat
2026-03-250.3063 CNY0.3414 CNY-10.3%Miss
2025-10-230.1999 CNY0.2958 CNY-32.4%Miss
2025-08-200.3974 CNY0.3129 CNY+27%Beat
2025-05-300.29 CNY0.2925 CNY-0.9%Miss
2024-12-310.2707 CNY0.21 CNY+28.9%Beat
2024-10-240.19 CNY0.23 CNY-17.4%Miss
2024-08-210.33 CNY0.33 CNY0%Beat

Beat rate: 4/8 (50%) over reported quarters with consensus data.

600276.SS valuation and analyst view

Trailing P/E43.93
Trailing EPS1.231 CNY
Price / book5.69
Dividend yield0.36%
Market cap353.33B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Jiangsu Hengrui Medicine (600276.SS)'s next earnings date?

Jiangsu Hengrui Medicine is next scheduled to report on 2026-08-20, with a consensus EPS estimate of 0.3717 CNY and revenue estimate of 9.02B.

Did 600276.SS beat earnings last quarter?

In its 2026-04-22 report, 600276.SS posted EPS of 0.3369 CNY versus a 0.3275 CNY estimate — a beat of 2.9%.

What is 600276.SS's earnings track record?

Over the last 8 reported quarters with consensus data, 600276.SS beat estimates 4 times (50%).

What is 600276.SS's current P/E ratio and EPS?

600276.SS trades at a trailing P/E of 43.93 on trailing EPS of 1.2305598766115993 CNY.

What do analysts rate 600276.SS?

600276.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.